

1 Longitudinal analysis at three oral sites links oral microbiota to 2 clinical outcomes in allogeneic hematopoietic stem-cell transplant

3 Vitor Heidrich^{1,2}, Franciele H. Knebel¹, Julia S. Bruno¹, Vinícius C. de Molla^{3,4}, Wanessa
4 Miranda-Silva¹, Paula F. Asprino¹, Luciana Tucunduva⁵, Vanderson Rocha⁶, Yana Novis⁵,
5 Eduardo R. Fregnani¹, Celso Arrais-Rodrigues^{3,4}, Anamaria A. Camargo^{1,*}

6 ¹Centro de Oncologia Molecular, Hospital Sírio-Libanês, São Paulo, SP, Brazil

7 ²Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, SP,
8 Brazil

9 ³Hospital Nove de Julho, Rede DASA, São Paulo, SP, Brazil

10 ⁴Universidade Federal de São Paulo, São Paulo, SP, Brazil

11 ⁵Centro de Oncologia, Hospital Sírio-Libanês, São Paulo, SP, Brazil

12 ⁶Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo/Instituto do Câncer do
13 Estado de São Paulo (ICESP), São Paulo, SP, Brazil

14 *Corresponding author

15 Authors' email addresses

16 VH: vheidrich@mochsl.org.br

17 FHK: fhknebel@mochsl.org.br

18 JSB: juliasb9@gmail.com

19 VCM: viniciuscamposdemolla@gmail.com

20 WMS: wmswanessa@yahoo.com.br

21 PFA: pasprino@mochsl.org.br

22 LT: luciana.tucunduva@gmail.com

23 VR: rocha.vanderson@hotmail.fr

24 YN: yananovis@yahoo.com

25 EFR: eduardofregnani@me.com

26 CAR: celsoarrais@gmail.com

27 AAC: anamaria.acamargo@hsl.org.br

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 **Abstract**

29 **Background**

30 Allogeneic hematopoietic stem-cell transplant (allo-HSCT) is a potentially curative therapy
31 for several hematological disorders. Before stem-cell infusion, recipients undergo a
32 conditioning regimen with chemo/radiotherapy and immunosuppressants, requiring the use
33 of antibiotics to treat and prevent infections. This regimen promotes drastic alterations in the
34 recipient's microbiotas, including the oral microbiota, which have been associated with allo-
35 HSCT complications and poor outcomes. However, long-term longitudinal studies on the oral
36 microbiota of allo-HSCT recipients are scarce and disregard the existence of distinct
37 microbiotas within the oral cavity. Here, we used 16S rRNA gene sequencing to characterize
38 the microbiota dynamics (during and after allo-HSCT) of 31 allo-HSCT recipients at 3 oral
39 sites (gingival crevicular fluid, oral mucosa, and supragingival biofilm).

40 **Results**

41 Analysis of the oral microbiota dynamics during allo-HSCT revealed a significant decline in
42 bacterial diversity and major shifts in microbiota composition in all oral sites, including
43 blooms of potentially pathogenic genera. These blooms in some cases preceded respiratory
44 infections caused by the blooming genera. We also noticed that differences in microbiota
45 diversity and composition between oral sites were lost during allo-HSCT. Overall, oral
46 microbiotas returned to their preconditioning state after engraftment. However, the ability to
47 recover the initial bacterial composition varied between patients. After stratifying patients
48 based on their ability to recover their preconditioning microbiota composition, we found that
49 recovery of the oral mucosa microbiota composition was not associated with antibiotic usage
50 but was associated with higher preconditioning diversity and earlier reconstitution of normal
51 leukocyte counts. Most notably, oral mucosa microbiota composition recovery was an
52 independent biomarker of better allo-HSCT outcomes.

53 **Conclusion**

54 We observed clear patterns of microbiota dysbiosis in all three oral sites during allo-HSCT,
55 however each oral site responded differently to the perturbations associated with allo-HSCT.
56 Oral microbiota injury and recovery patterns were associated with allo-HSCT complications
57 and outcomes. This study highlights the potential clinical impact of the oral microbiota in the
58 allo-HSCT setting and the clinical value of tracking oral microbiota changes during allo-
59 HSCT.

60 **Keywords**

61 Oral microbiome; 16S rRNA gene sequencing; allogeneic hematopoietic cell transplant;
62 microbiome stability; blooming of bacteria; biomarkers; clinical outcomes.

63 **Introduction**

64 Countless microbes from food, air, and our physical/biological environment arrive in
65 our mouths daily. However, only a small subset of these microbes can colonize the oral
66 cavity to compose the oral microbiota [1]. This constant contact with non-resident microbes
67 and frequent exposure to other insults (e.g., toothbrushing) made the human oral microbiota
68 remarkably stable and resilient to external perturbations [2].

69 Residing oral microbes organize in biofilms, creating oxygen gradients that allow
70 colonization by both anaerobic and aerobic bacteria [1]. Differences in moisture, topography,
71 and tissue type (shedding vs. non-shedding), among others, make each oral site home to
72 distinct bacterial communities [1, 3] with main compositional differences existing between
73 mucosa-associated and teeth-associated microbiotas [4].

74 These distinct oral microbiotas are important regulators of human health, as they
75 have been associated with different local and systemic disorders [5]. While the supragingival
76 biofilm is causally linked to the pathogenesis of dental caries [6], bacteria at the gingival
77 crevice, an oxygen-limited environment bathed in immune exudate (gingival crevicular fluid),
78 are linked to periodontitis [7] and may cause bacteremia by translocation to the circulation

79 across the thin gingival crevice epithelium [8]. Oral bacteria can further facilitate systemic
80 reach by producing molecules that increase vascular permeability [5]. Using this strategy,
81 oral *Porphyromonas gingivalis* is able to colonize the brain, contributing to the pathogenesis
82 of Alzheimer's disease [9].

83 Allogeneic hematopoietic stem-cell transplant (allo-HSCT) is used to treat malignant
84 (e.g., acute myeloid leukemia) and non-malignant (e.g., aplastic anemia) hematological
85 disorders [10]. The goal of allo-HSCT is to eradicate malignant/defective cells and to replace
86 an abnormal hematopoietic and immune system [11]. Allo-HSCT recipients undergo a
87 conditioning regimen with chemo/radiotherapy that reduces disease burden and provides
88 sufficient immunoablation to allow donor stem-cell engraftment [12]. After engraftment, the
89 graft-vs-tumor/autoimmunity effect further promotes disease eradication and the
90 hematopoietic/immune function gradually reconstitutes [13]. Besides chemo/radiotherapy,
91 allo-HSCT recipients are treated with immunosuppressants to prevent engraftment failure
92 and graft-vs-host disease, and antibiotics to prevent and treat opportunistic infections during
93 immunosuppression [13, 14].

94 Allo-HSCT is considered one of the most severe perturbations the immune system
95 undergoes in the therapeutic setting [15]. Since the immune system regulates microbiota
96 composition [16] and chemotherapy [17], radiotherapy [18], and antibiotics [19] have
97 detrimental effects on the microbiota, drastic alterations in the gut microbiota have been
98 reported in allo-HSCT recipients, including loss of bacterial diversity and blooms of
99 potentially pathogenic species [20]. Recent evidence shows these alterations extend to other
100 microbiotas [21], including the relatively more stable oral microbiota [22–26]. More
101 importantly, the pre-transplant microbiota and the extent of microbiota damage during allo-
102 HSCT are associated with allo-HSCT complications and outcomes, so that gut and oral
103 microbiota provide biomarkers in the allo-HSCT setting [24, 25, 27–30].

104 The stability of the oral microbiota [5] and its associations with allo-HSCT outcomes
105 offer a unique opportunity to identify predictive biomarkers and develop therapeutic
106 interventions to promote oral health in allo-HSCT recipients, potentially improving allo-HSCT

107 safety and efficacy. However, so far, oral microbiota studies in allo-HSCT recipients
108 evaluated single oral sites, not leveraging the ease of sampling of different oral
109 compartments [22–26, 30]. In addition, although a causal link between post-transplant gut
110 microbiota recovery and improved clinical responses to allo-HSCT has been suggested [15],
111 oral microbiota recovery trajectories after allo-HSCT were not thoroughly characterized and
112 their association with allo-HSCT outcomes remain unknown.

113 To obtain a more in-depth understanding of oral microbiota dynamics during and
114 after allo-HSCT and to test whether oral microbiota recovery is associated with allo-HSCT
115 outcomes, we profiled the oral microbiota of a Brazilian cohort of allo-HSCT recipients. We
116 collected over 440 samples encompassing five timepoints and three oral sites: gingival
117 crevicular fluid (GCF), oral mucosa (OM), and supragingival biofilm (SB), which allowed a
118 longitudinal anatomically-aware analysis of the oral microbiota. We used 16S rRNA gene
119 sequencing to characterize diversity, compositional, and taxonomical changes in oral
120 microbiota during allo-HSCT and after engraftment. We associated these changes with
121 antibiotic usage and allo-HSCT complications. Finally, we evaluated recovery trajectories
122 after allo-HSCT to associate oral microbiota recovery with allo-HSCT outcomes.

123 **Materials and methods**

124 **Patients' clinical characteristics**

125 Thirty-one patients undergoing allo-HSCT at Hospital Sírio-Libanês (São Paulo,
126 Brazil) were recruited between January 2016 and April 2018. The median age was 50 years,
127 most patients were male (55%), and acute leukemia was the most common underlying
128 disease (58%; 11 acute myeloid leukemia and 7 acute lymphocytic leukemia cases). Most
129 patients underwent reduced intensity conditioning (61%) and received grafts from peripheral
130 blood (68%). Patient clinical information is summarized in Table S1.

131 **Antibiotic usage analysis**

132 Antibiotic prescriptions were retrieved retrospectively from clinical records.
133 Information spanning 30 days before preconditioning sampling and 100 days after stem-cell
134 infusion was collected to build timelines of antibiotic usage for each patient (Additional file 1:
135 Timelines of antibiotic usage). A ridgeline plot of antibiotic usage detailing all antibiotics and
136 antibiotic classes used showed antibiotics prescription concentrates in the few weeks
137 immediately after infusion (Fig. S1), with only 5/31 patients receiving antibiotics before
138 preconditioning (Additional file 1). Due to the sparse use of antibiotics before preconditioning
139 and the unlikely effect of antibiotics received months after allo-HSCT on clinical outcomes,
140 antibiotic usage was analyzed considering only the time window between preconditioning
141 and 30 days after engraftment (a patient deceased during this period was excluded from the
142 analysis). For each patient, the length in days under antibiotic therapy (length of therapy,
143 LOT) and the number of agent days under antibiotic therapy (days of therapy, DOT) was
144 calculated, as defined previously [31]. To evaluate the impact of specific antibiotic classes on
145 microbiota dynamics, patients were further classified according to antibiotic class usage
146 during the period of interest. Only antibiotic classes received by at least 20% of our patients
147 (6/30) were considered in this analysis. In addition to individual antibiotics prescriptions, all
148 patients underwent standard antimicrobial prophylaxis with antibiotic, antiviral and antifungal
149 drugs. Because the standard antibiotic prophylaxis protocol in our institution comprises oral
150 levofloxacin and sulfamethoxazole-trimethoprim, their use was not considered in the
151 antibiotic usage analysis.

152 **Sample collection**

153 Patients were examined frequently by an oral medicine specialist throughout the
154 hospitalization period. The standard oral hygiene protocol comprised toothbrushing with
155 fluoridated toothpaste and 0.12% chlorhexidine mouthwash. Samples were collected at least
156 six hours after the last oral hygiene procedure by an oral medicine specialist at three oral

157 sites. GCF samples were collected by inserting absorbent paper points in the gingival
158 crevice; OM samples were collected by swabbing bilateral buccal mucosa, alveolar mucosa
159 of the jaws, and tongue dorsum; SB samples were collected by swabbing all vestibular
160 enamel surface. Samples were dry-stored at -20°C.

161 **DNA extraction and 16S rRNA gene amplicon sequencing**

162 Samples were brought to room temperature. Bacterial cells were recovered from
163 swabs or paper points by vortexing in 600 µl or 800 µl TE buffer (10mM Tris; 1mM EDTA; pH
164 8.0), respectively. Samples were transferred to a new tube, supplemented with 6 µl (OM and
165 SB) or 8 µl (GCF) PureLink™ RNAse A (20 mg/ml; Invitrogen), and DNA was extracted using
166 the QIAamp DNA Mini Blood kit (Qiagen) following the manufacturer's protocol (*Buccal*
167 *Swab Spin Protocol*).

168 Bacterial communities were profiled by 16S rRNA gene amplicon-sequencing as
169 described in detail previously [32]. In short, amplicon libraries were prepared with 12.5 ng of
170 total DNA and pre-validated V3V4 primers [33] following Illumina's protocol (*Preparing 16S*
171 *Ribosomal RNA Gene Amplicons for the Illumina MiSeq System*). Amplicons were
172 sequenced on the Illumina MiSeq platform using the MiSeq Reagent Kit v3 (600-cycle)
173 (Illumina).

174 **Bioinformatics pipeline**

175 Reads were demultiplexed using the MiSeq Reporter Software. Primers were
176 removed and low-quality 3' ends were trimmed using *seqtk* [34]. Next, reads were processed
177 using QIIME 2 (v2019.10.0) as schematized in Fig. S2a [35]. In detail, amplicon sequence
178 variants (ASVs) were generated using the DADA2 pipeline (via *q2-dada2*), which includes
179 removal of low-quality reads, denoising, merging, and removal of bimeras [36]. Chimeric
180 ASVs were further filtered out using a reference-based approach with VSEARCH [37] (via
181 *q2-vsearch*) and SILVA database (v132) [38]. Taxonomic assignment of ASVs was also
182 performed with VSEARCH [37] (via *q2-feature-classifier*) and SILVA (v132) [38]. Finally,

183 non-bacterial ASVs were removed (via *q2-feature-table*). QIIME 2 outputs were transferred
184 to the R environment [39] using the *qiime2R* R package [40] and analyzed for microbiota
185 profiling with custom R scripts as detailed below.

186 **Microbiota and statistical analyses**

187 The total number of reads of the sample with the lowest number of reads (3,578
188 reads) among the samples included in the microbiota profiling analyses was used as C_{\min} for
189 Scaling with Ranked Subsampling (SRS) normalization prior to diversity analyses [41].
190 Diversity was measured by the Gini-Simpson index [42] using the *phyloseq* R package [43].
191 Longitudinal diversity variations were evaluated by calculating diversity resistance,
192 resilience, and stability [44, 45] (see Additional file 3: Supplementary methods).
193 Compositional dissimilarity between samples was measured by the weighted UniFrac
194 distance [46] using the *rbiom* R package [47]. Longitudinal compositional variations were
195 evaluated by calculating compositional stability (see Additional file 3). Multiple linear
196 regression was used to evaluate whether antibiotic usage was associated with diversity
197 stability and compositional stability (see Additional file 3). Recovery to baseline composition
198 was defined as distance between samples collected at preconditioning and 30 days after
199 engraftment <0.5 .

200 Taxonomic nomenclature was homogenized prior to all taxonomic analyses (see
201 Additional file 3). Taxa relative abundance plots included only the most relevant genera
202 according to criteria specified in figure legends. Differential abundance analysis was
203 performed using ANCOM-BC [48] with genera present in $\geq 25\%$ of the samples being
204 compared. Genera abundance differences between groups at q -value < 0.05 (Bonferroni
205 correction) were considered statistically significant, including ANCOM-BC structural zeroes.

206 Associations between oral microbiota composition recovery or clinical parameters
207 with allo-HSCT outcomes were determined using univariate Cox proportional-hazards
208 regression [49] or univariate Fine-Gray competing risk regression [50]. Cox models were
209 used to evaluate overall survival and progression-free survival, while Fine-Gray models were

210 used to evaluate the risk of transplant-related death (with relapse mortality as competing
211 risk) and the risk of underlying disease relapse (with transplant-related mortality as
212 competing risk). Multivariate analysis was used to evaluate oral microbiota composition
213 recovery and correct for clinical parameters significantly associated with the outcome (P-
214 value < 0.05) in the univariate analysis. Patients experiencing the event before oral
215 microbiota composition recovery evaluation were excluded from univariate and multivariate
216 analyses.

217 **Results**

218 **Samples collected and sequencing output**

219 We collected samples from three oral sites (GCF, OM, and SB) at five timepoints
220 during allo-HSCT: preconditioning (P), aplasia (A), engraftment (E), 30 days after
221 engraftment (E30), and 75 days after engraftment (E75). Since most patients were
222 discharged shortly after engraftment, the exact date of sample collection varied for E30 (20–
223 45 days after engraftment) and E75 (60–131 days after engraftment) samples, as indicated
224 in Fig. S3. Premature death after allo-HSCT hampered the collection of the E30 sample for
225 patient #3 and E75 samples for patients #1, #2, #3, #21, and #31 (Fig. S3). In addition, the
226 E75 sample from patient #9 was excluded due to low DNA yield. Overall, 444 samples were
227 successfully processed and sequenced for microbiota profiling.

228 We generated a total of 53,253,725 V3V4 16S rRNA reads (median per sample:
229 104,230.5; range: 2,059–502,409; Fig. S2b). After filtering, 31,343,619 reads (59%; Fig.
230 S2c–d) were retained (median per sample: 63,075.5; range: 87–310,082; Fig. S2e),
231 corresponding to 4,046 ASVs. Using SRS curves [51] (Fig. S4), we established a minimum
232 sequencing depth cutoff of 3,000 reads and 4 low-depth samples were excluded from further
233 analysis (patient #1, OM, P; #5, OM, E; #6, OM, E; #25, SB, E). We proceeded to profile the
234 oral microbiota during allo-HSCT with 440 samples.

235 **Compositional differences between oral microbiotas during allo-HSCT and after** 236 **engraftment**

237 We first assessed microbiota compositional differences between oral sites at each
238 allo-HSCT timepoint. Visually, all three oral microbiotas occupied a similar compositional
239 space throughout allo-HSCT (Fig. 1a). Nevertheless, similarly to what is observed in healthy
240 adults [4], each oral site contained a significantly different microbiota composition at P
241 (PERMANOVA, GCF vs. OM: P-value = 0.001; GCF vs. SB: P-value = 0.002; OM vs. SB: P-
242 value = 0.018). Noteworthy, these differences progressively diminished in subsequent
243 timepoints until E30 and were partially recovered at E75 (Fig. 1b). Calculation of the
244 minimum compositional distance between oral sites for each patient confirmed lower
245 compositional distance between sites after P (Fig. 1c).

246 Differential abundance analysis at genus level using ANCOM-BC revealed a similar
247 picture (Fig. 1d). As expected, all three oral microbiotas showed many distinguishing genera
248 at P. For example, we observed a higher abundance of *Actinomyces* in the SB as compared
249 to GCF and a higher abundance of *Solobacterium* in the OM as compared to SB (Fig. S5).
250 *Actinomyces spp.* are early colonizers of the SB with a crucial role in ecological succession
251 during SB maturation [52]. On the other hand, *Solobacterium moorei*, the only known
252 species in the *Solobacterium* genus, is a halitosis-associated bacteria typically found in the
253 tongue dorsum [53], a site contemplated in OM samples. However, a smaller number of
254 differentially abundant genera was observed in subsequent timepoints, with a slight increase
255 in the number of differentially abundant genera between sites at E75, illustrated by the
256 reappearance of *Solobacterium* as an OM-associated genus (Fig. S5).

257 In short, our data indicate that compositional differences between oral microbiotas
258 are reduced during allo-HSCT, being only partially recovered several weeks after
259 engraftment.

260 **Oral microbiota dynamics during allo-HSCT and after engraftment**

261 We next characterized microbiota diversity dynamics at each oral site during allo-
262 HSCT and after engraftment. As previously shown for OM [25] and SB [24], GCF presented
263 a stepped decline in diversity up to E (Fig. 2a). By extending this analysis to the post-
264 engraftment period for all oral sites, we observed a gradual recovery of diversity, with
265 baseline levels almost fully reestablished around E75.

266 We then applied key concepts from ecology [45] for a more in-depth characterization
267 of diversity dynamics during allo-HSCT. By considering allo-HSCT as a perturbation relieved
268 immediately after engraftment, we calculated for each patient diversity resistance (inversely
269 proportional to the diversity loss up to E), resilience (rate of diversity gain after E), and
270 stability (combined effect of resistance and resilience) to allo-HSCT (Fig. S6a; see Additional
271 File 3). GCF showed higher diversity resistance than OM and SB (Fig. 2b), in line with the
272 less pronounced loss of diversity observed in this oral site at E (Fig. S6b). All oral sites
273 presented equivalent levels of diversity resilience and stability (Fig. 2b), in line with the
274 similar levels of diversity after engraftment observed for all oral sites (Fig. S6b).

275 Next, we characterized compositional changes in each oral site during allo-HSCT
276 and after engraftment. The compositional distance to P centroid increased up to E and
277 decreased in the post-engraftment period, indicating a displacement from and posterior
278 recovery to baseline compositions (Fig. 1c). However, when comparing the compositional
279 distance from P to all other timepoints using PERMANOVA tests, we observed that GCF and
280 SB post-engraftment samples still showed significantly different compositions after
281 engraftment compared to P, while OM samples more fully recovered their preconditioning
282 state (Fig. 1d). Finally, in analogy to diversity stability, we calculated the compositional
283 stability for each patient (see Additional File 3). As observed for diversity stability, all oral
284 sites showed equivalent levels of compositional stability (Fig. S6c).

285 Our data indicate that allo-HSCT transiently damages oral microbiotas diversity and
286 composition, but each oral site responds differently to the perturbations associated with allo-
287 HSCT.

288 **Oral taxa abundances during allo-HSCT and after engraftment**

289 The loss of differences between microbiotas of distinct oral sites and the
290 displacement from initial compositions observed during allo-HSCT point out to a complex
291 compositional dynamics that likely involves many bacterial taxa and thus can be better
292 appreciated by longitudinal taxonomic composition analysis at each specific site. As
293 expected, all oral sites presented high relative abundance of commensal bacteria at P (Fig.
294 3a; Fig. S7). For instance, *Veillonella* and *Streptococcus*, genera with high relative
295 abundance in all oral sites of healthy adults [4], occupied either the first or second position in
296 terms of mean relative abundance at P in all three oral sites (Fig. 3b). However, there were
297 several changes in the ranking of the most abundant taxa (on average) across timepoints
298 (Fig. 3b; Fig. S7), pointing to drastic taxonomic composition changes during allo-HSCT.
299 There are some noteworthy examples, such as *Streptococcus* in SB, which went from first in
300 the relative abundance ranking at P to the eleventh position at E. Interestingly,
301 *Streptococcus* recovered its initial ranking position after engraftment (first position at E30
302 and E75). On the other hand, some non-commensals genera were close to absent in P and
303 only emerged in the subsequent timepoints. For instance, *Enterococcus* and *Lactobacillus*,
304 both potentially pathogenic genera in the oral microbiota [54, 55], showed low mean relative
305 abundance at P but were among the most abundant genera in all sites at E.

306 Differential abundance analysis at genus level using ANCOM-BC with P as reference
307 for comparisons confirmed these results and showed several additional differentially
308 abundant genera (Fig. 3c). The number of differentially abundant genera at each timepoint
309 was consistent with the compositional displacement and recovery aforementioned, with a
310 maximum of differentially abundant genera at E (Fig. S8). Although there were considerably
311 fewer differentially abundant genera after engraftment, some differences persisted. For

312 instance, we observed a decreased abundance of *Catonella* in OM and SB, and of
313 Tannerella in GCF at E75, suggesting a long-lasting reduction of these genera caused by
314 allo-HSCT.

315 In summary, we observed that the dynamics of some commensal bacteria reproduce
316 the same pattern of displacement during allo-HSCT and recovery after engraftment
317 observed for the overall community. We also observed the emergence of opportunistic
318 potentially pathogenic genera during the most perturbed allo-HSCT phase which are capable
319 of colonizing all three oral sites and likely contribute to the loss of compositional differences
320 between oral microbiotas observed after preconditioning.

321 **Emergence of opportunistic genera and allo-HSCT complications**

322 The emergence of opportunistic genera during allo-HSCT can be more rigorously
323 quantified by assessing taxa blooms, defined as a taxon relative abundance increase from
324 <1% at P to dominance levels ($\geq 30\%$) at any subsequent timepoint. We have previously
325 shown, by analyzing this same cohort, blooms of specific genera occurring in SB during A
326 and E [24]. We now extended this analysis to other oral sites and to the post-engraftment
327 period. Overall, we detected 81 blooms, involving 22 genera and 27/31 patients. All oral sites
328 showed several blooming events, but SB blooms were more frequent (SB: $n = 35$; GCF: $n =$
329 24 ; OM: $n = 22$; Fig. 4a) and significantly more prevalent (SB: 23/31; GCF: 14/31; MO:
330 16/30; chi-square test, P -value = 0.022). Blooms typically occurred at E (53% of events; Fig.
331 4b) and were rapidly resolved in the post-engraftment period.

332 *Lactobacillus* (15%), *Enterococcus* (12%), and *Staphylococcus* (10%) were the
333 genera most frequently observed in blooming events in the oral microbiota during allo-HSCT
334 (Fig. 4c). But oral sites differed in the genera typically associated with blooms (Fig. 4d). SB
335 showed mainly *Enterococcus* (7 events) or *Lactobacillus* (6) blooms, while GCF showed
336 mostly *Staphylococcus* (4) or *Lactobacillus* (4) blooms. In contrast, OM blooms showed a
337 less clear signal of blooming genera. Nevertheless, some patients presented concomitant
338 blooms of the same genus in all oral sites.

339 We noticed that many of the blooming genera are potentially pathogenic for allo-
340 HSCT recipients. For instance, *Staphylococcus* genus contains species related to several
341 infections, including hospital-acquired pneumonia [56], an allo-HSCT complication with 15-
342 30% incidence [57]. Therefore, we evaluated whether blooming events in the oral microbiota
343 were associated with respiratory infections in our cohort. Between P and E75, only 3/31
344 patients presented bacterial respiratory infections (patients #1, #2, and #7). All three patients
345 showed blooms of genera in the oral microbiota during allo-HSCT. Specifically, patient #1
346 presented blooms of *Enterococcus* (in GCF and SB at E) and *Acetobacter* (in GCF and SB
347 at E30), patient #2 presented blooms of *Stenotrophomonas* (in all oral sites at E) and
348 *Mycoplasma* (in GCF at E), and patient #7 presented blooms of *Mycoplasma* (in OM and SB
349 at E). Interestingly, patients #1 and #2 presented blooms of the same genus identified in the
350 microbiological exam of their respiratory tract samples: *Enterococcus* and
351 *Stenotrophomonas*, respectively. Importantly, these blooms preceded the clinical
352 manifestation of the respiratory infection by one and two weeks, respectively, suggesting a
353 potential oral origin for the bacteria associated with the respiratory infections in these cases.
354 On the other hand, patient #7 developed a respiratory infection caused by *Escherichia coli*
355 between E30 and E75, which was unrelated to the blooms detected for this patient.

356 Given the apparent translocation of abundant oral bacteria to the respiratory tract in
357 our cohort and the well-known association between intestinal dominance and bacteremia
358 during allo-HSCT [58], we also tested whether blooming events in the oral microbiota were
359 associated with bacteremia events. Positive blood cultures for bacteria were detected for
360 15/31 patients between P and E75. We did not find an association between oral microbiota
361 blooms and altered odds of bacteremia (Fisher's exact test, GCF bloom: OR = 3.17, P-value
362 = 0.156; OM bloom: OR = 2.25, P-value = 0.299; SB bloom: OR = 0.92, P-value = 1; any
363 site bloom: OR = 3.12, P-value = 0.600). We detected a single case in which the blooming
364 of a genus in the oral microbiota preceded a bacteremia event with the same genus
365 involved. In detail, patient #14 presented blooms of *Enterococcus* in GCF and SB at A,
366 which preceded positive blood cultures for *Enterococcus* by 1.5 weeks.

367 Overall, we observed that blooms of opportunistic genera occur frequently in oral
368 microbiota during allo-HSCT, especially in SB. The examples described suggest oral
369 microbiota blooms during allo-HSCT may trigger translocation of oral microbes to the
370 respiratory tract (as often happens during oral microbiome dysbiosis [56]) and cause
371 respiratory infections in allo-HSCT recipients.

372 **Impact of antibiotic usage on oral microbiota dynamics**

373 To investigate the impact of antibiotic usage on oral microbiota dynamics and
374 blooming events during allo-HSCT, we analyzed antibiotic usage data between P and E30
375 (see Materials and Methods). Antibiotic usage varied widely across patients in terms of
376 length of therapy (LOT range: 0–58 days; median: 15.5 days) and days of therapy (DOT
377 range: 0–112 days; median: 22 days) (Table S1). Overall, 17 antibiotic agents (range: 0–10;
378 median: 3), spanning 12 distinct antibiotic classes (range: 0–9; median: 3 antibiotics) were
379 administered to our patients. The antibiotics administered to each patient are illustrated in
380 Fig. 5a. Most patients received cefepime (73%) and meropenem (63%), making
381 cephalosporins and carbapenems the most frequently used antibiotic classes: 73% and
382 63%, respectively (Fig. S9a). Glycopeptides and penicillins were also used in a considerable
383 proportion of patients: 60% and 23%, respectively. All other antibiotic classes were used by
384 less than 17% of our patients (Fig. S9b).

385 First, to assess the effect of antibiotic usage in microbiota dynamics, we modeled
386 diversity stability (which incorporates diversity resistance and resilience) and compositional
387 stability using antibiotic usage information (Table S2). We found that DOT significantly
388 predicted diversity stability during allo-HSCT for all oral sites, with prolonged use of antibiotic
389 therapy associated with lower diversity stability. However, the use of specific antibiotic
390 classes was not associated with altered diversity stability (Table S2). On the other hand,
391 DOT was not a predictor of compositional stability, but glycopeptide usage was significantly
392 associated with decreased SB compositional stability (Table S2). In addition, we found non-
393 significant associations at P-value < 0.1 between other antibiotic classes and decreased

394 compositional stability in GCF (cephalosporins and penicillins) and SB (cephalosporins),
395 while OM compositional stability was clearly less impacted by antibiotic usage during allo-
396 HSCT (Table S2).

397 We next tested whether blooms at different oral sites were associated with antibiotic
398 usage. E75 blooms were not considered in this analysis since our antibiotic usage survey
399 focused on the period between P and E30 (see Materials and Methods). With one exception
400 (glycopeptides and GCF blooms), the use of specific antibiotic classes was not associated
401 with blooms, but patients experiencing blooms showed higher LOT and DOT (Fig. 5b),
402 although it is not clear whether a more extended period under antibiotic therapy was the
403 cause or consequence of the blooms.

404 GCF blooms were significantly associated not only with LOT and DOT but also with
405 the use of glycopeptides (Fisher's exact test, odds ratio (OR) = 15.65, P-value = 0.006, P-
406 adjusted = 0.025), which enabled the investigation of the relation between the timing of
407 glycopeptide usage and GCF blooming events. GCF blooms occurred in 12 patients up to
408 E30, out of which 11 used glycopeptides (vancomycin and/or teicoplanin) between P and
409 E30. Notably, 10/11 patients that used glycopeptides and experienced GCF blooms received
410 glycopeptides a few days before or during the interval in which the bloom was detected,
411 indicating that glycopeptide usage during allo-HSCT may cause blooms of genera in the oral
412 microbiota.

413 The relationship between glycopeptide usage and blooming events and its
414 consequences can be illustrated by the genera composition trajectories and antibiotic usage
415 timeline of patients #1 and #2. Patient #2 experienced *Stenotrophomonas* blooms in all sites
416 at E, which occurred during the administration of vancomycin (Fig. 5c). Two weeks after
417 these blooms, patient #2 developed a respiratory infection caused by *Stenotrophomonas*
418 *maltophilia*, detected in microbiological exams of respiratory tract samples (e.g.,
419 bronchoalveolar lavage). Despite the intensification in the use of antibiotics,
420 *Stenotrophomonas* levels only rose in the oral microbiota after E, reaching staggering levels
421 at E30 (>95% relative abundance in all oral sites). Analysis at ASV level revealed that

422 *Stenotrophomonas* ASVs were absent in patient #2 at P (relative abundance = 0% in all oral
423 sites). At A, during the first course of vancomycin (Fig. 5c), a *Stenotrophomonas maltophilia*
424 ASV emerged in the SB (relative abundance = 0.02%). This ASV would later be responsible
425 for the blooms at E and the domination observed at E30. Taken together, these results
426 suggest that the use of vancomycin during allo-HSCT allowed the emergence and the bloom
427 of pathogenic *Stenotrophomonas maltophilia* in oral microbiota, which later translocated to
428 the respiratory tract, causing a respiratory infection. Patient #1 presented a similar picture
429 (Fig. S10), with the use of vancomycin followed by *Enterococcus* blooms and a subsequent
430 respiratory infection caused by *Enterococcus faecium*. Notably, patients #1 and #2 died
431 before E75, with death causes at least partially associated with their respiratory infections.

432 In summary, greater time of antibiotic exposure was associated with lower microbiota
433 diversity stability and blooms in all oral sites. Glycopeptide usage was associated with lower
434 microbiota compositional stability in SB and, although direct evidence is lacking, it seems
435 causally linked to some of the blooming events.

436 **Inter-patient variability in oral microbiota dynamics during allo-HSCT and after** 437 **engraftment**

438 To investigate inter-patient variability in oral microbiota dynamics during allo-HSCT
439 and after engraftment, we assessed longitudinal changes in oral microbiota in a patient-
440 centered analysis. Although most patients presented high diversity stability, which was
441 achieved either by having high resistance, high resilience, or a balance between the two,
442 some patients presented low diversity stability and even negative resilience values (Fig. 6a),
443 indicating loss of diversity after E. Curiously, this inter-patient variability was not due to
444 different levels of baseline diversity, since diversity at P was not correlated with diversity
445 resistance, resilience, nor stability (Fig. S11a). Compositional stability was also not
446 correlated with diversity levels at P (Fig. S11b)

447 In addition, when representing samples from all timepoints using Principal Coordinate
448 Analysis (PCoA), we noticed that confidence intervals for E samples were larger, indicating

449 considerable inter-patient compositional variability under perturbation (Fig. S11c). To confirm
450 this observation, we determined the most perturbed timepoint by quantifying the extent of
451 compositional shifts between timepoints. As presented in Fig. 6b, compositional changes
452 were more pronounced between A and E. Next, we evaluated inter-patient compositional
453 variability at each timepoint either by assessing the compositional distance between samples
454 and the respective timepoint centroid (Fig. 6c) or by calculating for each timepoint all
455 pairwise compositional distances (Fig. 6d). Both results confirmed maximum inter-patient
456 compositional variability at E under maximized perturbation, underscoring that allo-HSCT
457 modifies oral microbiota differently for each patient.

458 Finally, we investigated if this variability in oral microbiota dynamics during allo-HSCT
459 influenced oral microbiota recovery after engraftment. Although our results indicate that post-
460 engraftment samples overall occupy a similar compositional space in comparison to P, this
461 does not necessarily imply that patients recover their respective initial oral microbiota
462 compositions after engraftment. In order to evaluate oral microbiota compositional recovery
463 per patient, we analyzed the compositional distance from P for each patient and each site
464 during allo-HSCT and after engraftment. Interestingly, we noted that even though most
465 patients showed a recovery trajectory after engraftment, some did not (Fig. 6e).

466 Our data indicate a marked inter-patient variability in oral microbiota dynamics in
467 response to allo-HSCT. Despite oral microbiotas as a whole resembling preconditioning
468 microbiotas after allo-HSCT, patients differ in their ability to recover their initial oral
469 microbiota composition.

470 **Recovery of oral microbiota composition and allo-HSCT outcomes**

471 To investigate whether oral microbiota recovery after allo-HSCT was associated with
472 allo-HSCT outcomes we grouped our patients based on their ability to recover their
473 preconditioning composition. We calculated the compositional distance between P and E30,
474 and classified patients as recoverers (distance <0.5) or non-recoverers (distance ≥ 0.5). We
475 further illustrate these contrasting recovery behaviors using PCoA with compositional

476 trajectories of a representative OM recoverer and of an OM non-recoverer (Fig. 7a). PCoAs
477 for each patient are presented in Fig. S12. Overall, 77, 69, and 77% of our patients
478 recovered their initial GCF, OM, and SB microbiota composition after engraftment,
479 respectively (Fig. 7b).

480 Next, we used univariate analysis to investigate whether oral microbiota recovery
481 after allo-HSCT was associated with allo-HSCT outcomes (Table S3; Fig. S13). Interestingly,
482 OM recovery was associated with prolonged overall survival (OS; hazard ratio (HR) [95%
483 confidence interval (CI)] = 0.17 [0.05–0.52], P-value = 0.002; Fig. 7c), prolonged
484 progression-free survival (PFS; HR [95% CI] = 0.06 [0.01–0.34], P-value = 0.001; Fig. 7d),
485 and a lower risk of underlying disease relapse (HR [95% CI] = 0.20 [0.06–0.69], P-value =
486 0.011; Fig. 7e). OM recovery, however, was not associated with altered risk of transplant-
487 related death and GCF recovery or SB recovery were not associated with allo-HSCT
488 outcomes (Table S3; Fig. S13).

489 To identify possible confounding variables, we used univariate analysis to investigate
490 whether clinical parameters (including antibiotic usage; Table S1) were associated with allo-
491 HSCT outcomes (Table S4–7). We found that disease risk index (DRI), conditioning
492 intensity, and DOT were significantly associated with OS (Table S4). DRI was also
493 associated with PFS (Table S5) and the risk of underlying disease relapse (Table S6). We
494 then used a multivariate analysis to assess whether OM recovery was an independent
495 predictor of allo-HSCT outcomes (Table S8). In all cases, OM recovery remained
496 significantly associated with prolonged OS (HR [95% CI] = 0.09 [0.02–0.35], P-value <
497 0.001; Fig. 7f), prolonged PFS (HR [95% CI] = 0.09 [0.02–0.49], P-value = 0.005; Fig. 7g),
498 and with a lower risk of underlying disease relapse (HR [95% CI] = 0.19 [0.06–0.55], P-value
499 = 0.003; Fig. 7h). Taken together, these results robustly indicate that OM recovery at E30 is
500 an independent biomarker of better allo-HSCT outcomes.

501 **Underlying factors associated with oral mucosa microbiota recovery**

502 Given the relevant associations between OM recovery and allo-HSCT outcomes, we
503 searched for underlying factors associated with OM recovery. OM recovery was not
504 associated with clinical parameters such as age, underlying disease, and graft source (Table
505 S9). The usage of specific antibiotic classes, LOT, and DOT between P and E30 were also
506 not associated with OM recovery (Table S9; Fig. S14a). In addition, OM recoverers and non-
507 recoverers showed similar intervals between stem-cell infusion and engraftment (Fig. S14b).

508 We also evaluated whether OM microbiota characteristics could be related to OM
509 recovery. OM recoverers did not show higher OM diversity at E30 (Fig. 8a), indicating OM
510 non-recoverers did not necessarily possess dysbiotic OM microbiotas at E30. In line with
511 this, OM blooms throughout allo-HSCT were not more frequent among OM non-recoverers
512 (Fisher's exact test, OR = 4.07, P-value = 0.13). On the other hand, OM recoverers showed
513 higher OM diversity at P and E (Fig. 8a). In fact, there was a significant negative correlation
514 between OM diversity at P and the compositional distance between P and E30 (Fig. 8b).
515 This effect was not observed for GCF and SB (Fig. 8b).

516 Lastly, we investigated if earlier reconstitution of blood cell counts was associated
517 with OM recovery (see Additional File 3; Fig. 8c). Blood cell counts at P or E were not
518 associated with OM recovery. Interestingly, however, OM recoverers showed higher
519 leukocyte counts at E30, which is mostly due to significantly higher neutrophil and
520 lymphocyte counts in this group. Furthermore, normal (within reference values) leukocyte
521 counts at E30 were more frequently observed among OM recoverers compared to OM non-
522 recoverers (16/20 vs. 3/9, respectively; Fisher's exact test, P-value = 0.032) and OM
523 recoverers presented higher leukocyte counts throughout one year after allo-HSCT
524 compared to non-recoverers due to the combined contribution of higher neutrophil,
525 lymphocyte, and monocyte counts (Fig. S14c).

526 In summary, we found independent (blood cell counts) and non-independent (OM
527 microbiota at P) parameters to illuminate the differences between OM recoverers and non-

528 recoverers. OM recovery was associated with higher diversity at P, indicating more diverse
529 OM communities are more competent in recovering their pre-perturbation compositions. In
530 addition, OM recoverers showed higher leukocyte counts at E30, suggesting an association
531 between OM microbiota composition recovery and earlier immune system reconstitution.

532 Discussion

533 The anatomical complexity of the oral cavity provides a multitude of physicochemical
534 environments for microbes to thrive [1, 3]. Although several dozen core bacterial genera
535 inhabit all oral compartments, different species occupy each oral niche, meaning oral
536 microbes are site-specialists that compose distinct microbiotas in each oral environment [1,
537 59]. We and others have previously reported the impact of allo-HSCT in oral microbiotas and
538 their associations with allo-HSCT complications and outcomes [22–26, 30]. However, these
539 studies analyzed single oral sites and were mostly limited to the peri-engraftment period of
540 allo-HSCT. To our knowledge, this is the first study to evaluate the impact of allo-HSCT in
541 the microbiota of various oral sites simultaneously during and after allo-HSCT.

542 We found that the microbiota of all oral sites was severely damaged by allo-HSCT,
543 but each site responded differently to the perturbations associated with allo-HSCT.
544 Compositional differences between oral sites were lost during allo-HSCT and partially
545 recovered after engraftment. Oral microbiota injury was marked by loss of diversity and
546 emergence of opportunistic potentially pathogenic genera. Notably, these opportunistic
547 genera could colonize all three oral sites and likely contributed to the loss of compositional
548 differences between oral microbiotas observed after conditioning. Colonization by
549 opportunistic genera was more common at E, explaining the higher compositional variability
550 and lower diversity observed at E, which we found to be the most perturbed allo-HSCT
551 phase for all oral sites. This is in line with the Anna Karenina Principle applied to host-
552 associated microbiomes [60], which states that more diverse communities tend to be more

553 compositionally similar, while perturbed communities tend to occupy several alternative
554 dysbiotic states.

555 Blooms of opportunistic genera were associated with prolonged antibiotic exposure
556 and the use of glycopeptides. This association is clinically relevant in the allo-HSCT setting
557 since glycopeptide-resistant bacteria (e.g., vancomycin-resistant enterococci) are a common
558 cause of infections in the hospital environment [61], especially in immunosuppressed
559 individuals. In addition, we observed that, in some cases, oral microbiota blooms preceded
560 respiratory infections caused by the blooming bacteria, linking the oral microbiota dynamics
561 during allo-HSCT to a common allo-HSCT complication [62], probably due to translocation of
562 oral bacteria to the respiratory tract through aspiration [56]. Similarly to our study, Thänert et
563 al. (2019) showed pathobiont blooms in the gut microbiota often preceded urinary tract
564 infections, but, as observed here, not all blooms were associated with subsequent infection
565 [63]. Interestingly, even though the mouth is a highly vascularized organ and the existence of
566 an oral-blood translocation axis has been proposed [64], we did not find a clear association
567 between oral bacteria blooms and bacteremia events during allo-HSCT.

568 Respiratory infections following blooms were caused by *E. faecium* in patient #1 and
569 *S. maltophilia* in patient #2. *S. maltophilia* colonization has been reported in 7% of allo-HSCT
570 recipients and is associated with higher non-relapse mortality risk due to higher odds of
571 invasive *S. maltophilia* infections [65]. Our results highlight that nosocomial bacteria such as
572 *S. maltophilia* can colonize the oral cavity during allo-HSCT. These results point to the
573 importance of maintaining oral health during allo-HSCT not only to prevent oral but also
574 distal complications (e.g., hospital-acquired pneumonia) [56]. Furthermore, our results
575 suggest that tracking drastic oral microbiota changes during allo-HSCT may guide early
576 interventions to prevent infections. This will be especially useful when the causative agent is
577 not a common respiratory pathogen such as in the case of *E. faecium* [66].

578 Longitudinal analysis of oral microbiota diversity and composition showed post-
579 transplant oral microbiotas were overall similar to preconditioning microbiotas, but patient-
580 level analysis showed that 23-31% of the patients did not recover their preconditioning

581 microbiota composition. Variability in gut microbiota recovery following a perturbation has
582 been previously described [67, 68], including after allo-HSCT, where most patients (>90%)
583 were unable to recover their initial gut microbiota composition [68]. The higher proportion of
584 patients that recovered their preconditioning composition in our study suggests that the oral
585 microbiota is more resilient to the perturbations associated with allo-HSCT than the gut
586 microbiota. This result is in line with a previous study showing that the oral microbiota is
587 more resilient than the gut microbiota to antibiotic perturbation [69].

588 Pre-perturbation microbiota characteristics, such as the presence of keystone
589 bacteria, influence microbiota recovery [70]. Here, we found that patients that recovered their
590 OM microbiota composition after allo-HSCT showed higher preconditioning OM diversity,
591 indicating that more diverse OM microbiotas are more resilient to allo-HSCT. Our results
592 converge on the insurance hypothesis, which proposes that high-diversity communities are
593 less susceptible to perturbations [71]. Interestingly, in our study, OM compositional recovery
594 was not associated with the use of specific antibiotics nor with the duration of antibiotic
595 exposure. This is possibly because OM microbiota composition is not impacted by
596 antibiotics, as evidenced by the lack of associations between antibiotic usage and OM
597 compositional stability. Host genetics, reestablishment of normal diet, and reconstitution of
598 the immune system are other possible drivers of microbiota recovery after allo-HSCT. Here,
599 we showed that leukocyte blood counts at E30 were higher in patients that recovered their
600 OM microbiota composition, indicating a close link between early immune system
601 reconstitution and oral microbiota recovery. We can speculate that immune reconstitution
602 allows stricter control of microbiota compositions (e.g., via immunoglobulin A [72]), which,
603 along with reestablishment of microbial environment (e.g., normal diet), supports the
604 recovery of the initial OM microbiota composition [73, 74].

605 The ability to recover the OM initial microbiota composition was associated with
606 better allo-HSCT outcomes. However, it is unclear if OM microbiota recovery is just a
607 consequence or also a driver of early immune reconstitution, thus having a causal role in the
608 improved outcomes following allo-HSCT. Evidence from gut microbiota studies indicates that

609 the latter hypothesis is plausible [75]. For instance, recent studies have shown that specific
610 gut microbes are associated with immune cell dynamics post-allo-HSCT [15, 76]. Similarly,
611 Miltiadous et al. (2022) found that higher peri-engraftment gut microbiota diversity was
612 associated with higher lymphocyte counts 100 days after transplant [77]. In addition, murine
613 model experiments showed that gut microbiota supports immune reconstitution by allowing a
614 higher dietary energy uptake [78]. Most importantly, in a controlled randomized clinical trial,
615 patients who received autologous fecal microbiota transplant after allo-HSCT showed higher
616 leukocyte counts 100 days after engraftment, indicating recovery of the gut microbiota has a
617 causal role in facilitating immune system reconstitution [15]. If this causal relationship
618 extends to the oral microbiota, the use of therapeutic interventions to promote oral health
619 and microbiota recovery in allo-HSCT recipients, such as oral microbiota transplants [79],
620 could potentially improve allo-HSCT outcomes.

621 An important limitation of our study is its small sample size, which did not allow
622 underlying disease stratification to parse the effect of different diseases on oral microbiota
623 dynamics. Still, the longitudinal design, assessment of different oral sites, and evaluation of
624 a Brazilian cohort (a population underrepresented in human microbiome studies [80]) with
625 extensive metadata publicly available are strengths of our study that should be highlighted.
626 Also, to better address the influence of oral bacteria in immune cell dynamics, future studies
627 will have to combine high temporal resolution oral microbiota data with more deeply
628 phenotyped immune cell counts (e.g., flow cytometry data). In addition, since 16S rRNA
629 amplicon sequencing has limited taxonomic resolution, further studies should ideally be
630 performed using shotgun metagenomic sequencing, as this would allow strain-level
631 dynamics tracking. Finally, here and previously [24, 25], we showed that associations
632 between gut microbiota and allo-HSCT outcomes broadly extend to the oral microbiota.
633 However, studies with synchronous gut and oral microbiota profiling will be necessary to
634 decipher how these microbiotas are linked during allo-HSCT, especially considering the
635 higher translocation of oral bacteria along the oral-gut axis during disease [81].

636 **Conclusions**

637 The oral cavity is the ultimate doorway for microbes entering the human body. We
638 analyzed oral microbiotas dynamics in allo-HSCT recipients and showed that microbiota
639 injury and recovery patterns were highly informative on allo-HSCT complications and
640 outcomes. Our results highlight the importance of tracking recipient's microbiotas changes
641 during allo-HSCT to improve our understanding of allo-HSCT biology, safety, and efficacy.

642 **Availability of data and materials**

643 The bioinformatics pipeline used to process the sequencing data, the R scripts used
644 to run the analyses and generate the figures, and all clinical metadata (anonymized)
645 necessary to reproduce these results are available at [https://github.com/vitorheidrich/oral-](https://github.com/vitorheidrich/oral-microbiota-hsct)
646 [microbiota-hsct](https://github.com/vitorheidrich/oral-microbiota-hsct). Raw sequencing data have been deposited in the European Nucleotide
647 Archive (ENA) at EMBL-EBI under accession number PRJEB53914. Some samples
648 (analyzed in past studies) were deposited previously in ENA at EMBL-EBI under accession
649 numbers: PRJEB42862, PRJEB49175.

650 **Abbreviations**

651 *A*: Aplasia
652 *Allo-HSCT*: Allogeneic hematopoietic stem-cell transplant
653 *ASV*: Amplicon Sequence Variant
654 *CI*: Confidence interval
655 *DOT*: Days of therapy
656 *DRI*: Disease Risk Index
657 *E*: Engraftment
658 *E30*: 30 days after engraftment
659 *E75*: 75 days after engraftment
660 *E. faecium*: *Enterococcus faecium*

- 661 GCF: Gingival crevicular fluid
662 HR: Hazard ratio
663 LOT: Length of therapy
664 OM: Oral mucosa
665 OR: Odds ratio
666 OS: Overall survival
667 P: Preconditioning
668 PFS: Progression-free survival
669 SB: Supragingival biofilm
670 *S. maltophilia*: *Stenotrophomonas maltophilia*
671 SRS: Scaling with ranked subsampling

672 References

- 673 1. Welch JLM, Ramírez-Puebla ST, Borisy GG. Oral Microbiome Geography: Micron-Scale
674 Habitat and Niche. *Cell Host Microbe*. 2020;28:160–8.
- 675 2. Rosier BT, Marsh PD, Mira A. Resilience of the Oral Microbiota in Health: Mechanisms
676 That Prevent Dysbiosis. *J Dent Res*. 2018;97:371–80.
- 677 3. Proctor DM, Relman DA. The Landscape Ecology and Microbiota of the Human Nose,
678 Mouth, and Throat. *Cell Host Microbe*. 2017;21:421–32.
- 679 4. Segata N, Haake SK, Mannon P, Lemon KP, Waldron L, Gevers D, et al. Composition of
680 the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat
681 and stool samples. *Genome Biol*. 2012;13:R42.
- 682 5. Tuganbaev T, Yoshida K, Honda K. The effects of oral microbiota on health. *Science*.
683 2022;376:934–6.
- 684 6. Takahashi N, Nyvad B. The Role of Bacteria in the Caries Process: Ecological
685 Perspectives. *J Dent Res*. 2011;90:294–303.
- 686 7. Ng E, Tay JRH, Balan P, Ong MMA, Bostanci N, Belibasakis GN, et al. Metagenomic
687 sequencing provides new insights into the subgingival bacteriome and aetiopathology of
688 periodontitis. *J Periodontal Res*. 2021;56:205–18.
- 689 8. Gaffen SL, Moutsopoulos NM. Regulation of host-microbe interactions at oral mucosal
690 barriers by type 17 immunity. *Sci Immunol*. 2020;5:eaau4594.
- 691 9. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. *Porphyromonas*
692 *gingivalis* in Alzheimer’s disease brains: Evidence for disease causation and treatment with
693 small-molecule inhibitors. *Sci Adv*. 2019;5:eaau3333.
- 694 10. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la

- 695 Camara R, et al. Indications for haematopoietic cell transplantation for haematological
696 diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone
697 Marrow Transplant. 2022;57:1217–39.
- 698 11. Jenq RR, van den Brink MRM. Allogeneic haematopoietic stem cell transplantation:
699 individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010;10:213–21.
- 700 12. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell
701 transplantation: one size does not fit all. Blood. 2014;124:344–53.
- 702 13. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of Allogeneic Hematopoietic Stem
703 Cell Transplantation. Annu Rev Immunol. 2007;25:139–70.
- 704 14. Lehrnbecher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin M, et al.
705 Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic
706 Stem Cell Transplantation. Clin Infect Dis. 2020;71:226–36.
- 707 15. Schluter J, Peled JU, Taylor BP, Markey KA, Smith M, Taur Y, et al. The gut microbiota
708 is associated with immune cell dynamics in humans. Nature. 2020;588:303–7.
- 709 16. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health
710 and disease. Cell Res. 2020;30:492–506.
- 711 17. Ervin SM, Ramanan SV, Bhatt AP. Relationship Between the Gut Microbiome and
712 Systemic Chemotherapy. Dig Dis Sci. 2020;65:874–84.
- 713 18. Wang L, Wang X, Zhang G, Ma Y, Zhang Q, Li Z, et al. The impact of pelvic radiotherapy
714 on the gut microbiome and its role in radiation-induced diarrhoea: a systematic review.
715 Radiat Oncol Lond Engl. 2021;16:187.
- 716 19. Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H.
717 Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol. 2020;10.
- 718 20. Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem
719 cell transplantation. Nat Rev Cancer. 2018;18:283–95.
- 720 21. Sen T, Thummer RP. The Impact of Human Microbiotas in Hematopoietic Stem Cell and
721 Organ Transplantation. Front Immunol. 2022;13.
- 722 22. Ames NJ, Barb JJ, Ranucci A, Kim H, Mudra SE, Cashion AK, et al. The oral microbiome
723 of patients undergoing treatment for severe aplastic anemia: a pilot study. Ann Hematol.
724 2019;98:1351–65.
- 725 23. Shouval R, Eshel A, Dubovski B, Kuperman AA, Danylesko I, Fein JA, et al. Patterns of
726 salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem
727 cell transplantation. Blood Adv. 2020;4:2912–7.
- 728 24. Heidrich V, Bruno JS, Knebel FH, de Molla VC, Miranda-Silva W, Asprino PF, et al.
729 Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host
730 Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2021;12.
- 731 25. de Molla VC, Heidrich V, Bruno JS, Knebel FH, Miranda-Silva W, Asprino PF, et al.
732 Disruption of the oral microbiota is associated with a higher risk of relapse after allogeneic
733 hematopoietic stem cell transplantation. Sci Rep. 2021;11:17552.
- 734 26. Laheij AMGA, Rozema FR, Brennan MT, von Bültzingslöwen I, van Leeuwen SJM,
735 Potting C, et al. Long-Term Analysis of Resilience of the Oral Microbiome in Allogeneic Stem
736 Cell Transplant Recipients. Microorganisms. 2022;10:734.

- 737 27. Liu C, Frank DN, Horch M, Chau S, Ir D, Horch EA, et al. Associations between acute
738 gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell
739 transplant recipients and donors. *Bone Marrow Transplant*. 2017;52:1643–50.
- 740 28. Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland
741 JB, et al. Lactose drives *Enterococcus* expansion to promote graft-versus-host disease.
742 *Science*. 2019;366:1143–9.
- 743 29. Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, et al. Microbiota as
744 Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. *N Engl J Med*.
745 2020;382:822–34.
- 746 30. Oku S, Takeshita T, Futatsuki T, Kageyama S, Asakawa M, Mori Y, et al. Disrupted
747 tongue microbiota and detection of nonindigenous bacteria on the day of allogeneic
748 hematopoietic stem cell transplantation. *PLOS Pathog*. 2020;16:e1008348.
- 749 31. Stanić Benić M, Milanič R, Monnier AA, Gyssens IC, Adriaenssens N, Versporten A, et
750 al. Metrics for quantifying antibiotic use in the hospital setting: results from a systematic
751 review and international multidisciplinary consensus procedure. *J Antimicrob Chemother*.
752 2018;73 suppl_6:vi50–8.
- 753 32. Wang H, Altemus J, Niazi F, Green H, Calhoun BC, Sturgis C, et al. Breast tissue, oral
754 and urinary microbiomes in breast cancer. *Oncotarget*. 2017;8:88122–38.
- 755 33. Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, et al. Evaluation of
756 general 16S ribosomal RNA gene PCR primers for classical and next-generation
757 sequencing-based diversity studies. *Nucleic Acids Res*. 2013;41:e1.
- 758 34. Heng Li. seqtk: Toolkit for processing sequences in FASTA/Q formats.
- 759 35. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al.
760 Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.
761 *Nat Biotechnol*. 2019;37:852–7.
- 762 36. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2:
763 High-resolution sample inference from Illumina amplicon data. *Nat Methods*. 2016;13:581–3.
- 764 37. Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source
765 tool for metagenomics. *PeerJ*. 2016;4:e2584.
- 766 38. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA
767 ribosomal RNA gene database project: improved data processing and web-based tools.
768 *Nucleic Acids Res*. 2013;41:D590–6.
- 769 39. R Core Team. R: A language and environment for statistical computing. R Found Stat
770 Comput Vienna Austria. 2021.
- 771 40. Jordan E. Bisanz. qiime2R: Importing QIIME2 artifacts and associated data into R
772 sessions. 2018.
- 773 41. Beule L, Karlovsky P. Improved normalization of species count data in ecology by
774 scaling with ranked subsampling (SRS): application to microbial communities. *PeerJ*.
775 2020;8:e9593.
- 776 42. Simpson EH. Measurement of Diversity. *Nature*. 1949;163:688–688.
- 777 43. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis
778 and Graphics of Microbiome Census Data. *PLOS ONE*. 2013;8:e61217.

- 779 44. Orwin KH, Wardle DA. New indices for quantifying the resistance and resilience of soil
780 biota to exogenous disturbances. *Soil Biol Biochem.* 2004;36:1907–12.
- 781 45. Shade A, Peter H, Allison S, Baho D, Berga M, Buergmann H, et al. Fundamentals of
782 Microbial Community Resistance and Resilience. *Front Microbiol.* 2012;3.
- 783 46. Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R. UniFrac: an effective
784 distance metric for microbial community comparison. *ISME J.* 2011;5:169–72.
- 785 47. Daniel P. Smith. rbiom: Read/Write, Transform, and Summarize “BIOM” Data. 2022.
- 786 48. Lin H, Peddada SD. Analysis of compositions of microbiomes with bias correction. *Nat*
787 *Commun.* 2020;11:3514.
- 788 49. Cox DR. Regression Models and Life-Tables. *J R Stat Soc Ser B Methodol.*
789 1972;34:187–202.
- 790 50. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing
791 Risk. *J Am Stat Assoc.* 1999;94:496–509.
- 792 51. Heidrich V, Karlovsky P, Beule L. ‘SRS’ R Package and ‘q2-srs’ QIIME 2 Plugin:
793 Normalization of Microbiome Data Using Scaling with Ranked Subsampling (SRS). *Appl Sci.*
794 2021;11:11473.
- 795 52. Kolenbrander PE, Palmer RJ, Periasamy S, Jakubovics NS. Oral multispecies biofilm
796 development and the key role of cell–cell distance. *Nat Rev Microbiol.* 2010;8:471–80.
- 797 53. Barrak I, Stájer A, Gajdács M, Urbán E. Small, but smelly: the importance of
798 *Solobacterium moorei* in halitosis and other human infections. *Heliyon.* 2020;6:e05371.
- 799 54. Komiyama EY, Lepesqueur LSS, Yassuda CG, Samaranayake LP, Parahitiyawa NB,
800 Balducci I, et al. Enterococcus Species in the Oral Cavity: Prevalence, Virulence Factors and
801 Antimicrobial Susceptibility. *PLOS ONE.* 2016;11:e0163001.
- 802 55. Caufield PW, Schön CN, Saraithong P, Li Y, Argimón S. Oral Lactobacilli and Dental
803 Caries: A Model for Niche Adaptation in Humans. *J Dent Res.* 2015;94_9_suppl:110S-118S.
- 804 56. Dong J, Li W, Wang Q, Chen J, Zu Y, Zhou X, et al. Relationships Between Oral
805 Microecosystem and Respiratory Diseases. *Front Mol Biosci.* 2022;8.
- 806 57. Gudiol C, Sabé N, Carratalà J. Is hospital-acquired pneumonia different in transplant
807 recipients? *Clin Microbiol Infect.* 2019;25:1186–94.
- 808 58. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal
809 Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic
810 Stem Cell Transplantation. *Clin Infect Dis.* 2012;55:905–14.
- 811 59. Mark Welch JL, Dewhirst FE, Borisy GG. Biogeography of the Oral Microbiome: The
812 Site-Specialist Hypothesis. *Annu Rev Microbiol.* 2019;73:335–58.
- 813 60. Zaneveld JR, McMinds R, Vega Thurber R. Stress and stability: applying the Anna
814 Karenina principle to animal microbiomes. *Nat Microbiol.* 2017;2:1–8.
- 815 61. Cookson BD, Macrae MB, Barrett SP, Brown DFJ, Chadwick C, French GL, et al.
816 Guidelines for the control of glycopeptide-resistant enterococci in hospitals. *J Hosp Infect.*
817 2006;62:6–21.
- 818 62. Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious
819 complications after allogeneic hematopoietic stem cell transplantation. *J Infect Chemother.*
820 2016;22:505–14.

- 821 63. Thänert R, Reske KA, Hink T, Wallace MA, Wang B, Schwartz DJ, et al. Comparative
822 Genomics of Antibiotic-Resistant Uropathogens Implicates Three Routes for Recurrence of
823 Urinary Tract Infections. *mBio*. 2019;10:e01977-19.
- 824 64. Abed J, Maalouf N, Manson AL, Earl AM, Parhi L, Emgård JEM, et al. Colon Cancer-
825 Associated *Fusobacterium nucleatum* May Originate From the Oral Cavity and Reach Colon
826 Tumors via the Circulatory System. *Front Cell Infect Microbiol*. 2020;10.
- 827 65. Scheich S, Koenig R, Wilke AC, Lindner S, Reinheimer C, Wichelhaus TA, et al.
828 *Stenotrophomonas maltophilia* colonization during allogeneic hematopoietic stem cell
829 transplantation is associated with impaired survival. *PLOS ONE*. 2018;13:e0201169.
- 830 66. Li F, Wang Y, Sun L, Wang X. Vancomycin-resistant *Enterococcus faecium* pneumonia
831 in a uremic patient on hemodialysis: a case report and review of the literature. *BMC Infect*
832 *Dis*. 2020;20:167.
- 833 67. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the
834 human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci*. 2011;108
835 supplement_1:4554–61.
- 836 68. Vaitkute G, Panic G, Alber DG, Faizura-Yeop I, Cloutman-Green E, Swann J, et al.
837 Linking gastrointestinal microbiota and metabolome dynamics to clinical outcomes in
838 paediatric haematopoietic stem cell transplantation. *Microbiome*. 2022;10:89.
- 839 69. Zaura E, Brandt BW, Teixeira de Mattos MJ, Buijs MJ, Caspers MPM, Rashid M-U, et al.
840 Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the
841 Salivary Microbiome versus Long-Term Microbial Shifts in Feces. *mBio*. 2015;6:e01693-15.
- 842 70. Chng KR, Ghosh TS, Tan YH, Nandi T, Lee IR, Ng AHQ, et al. Metagenome-wide
843 association analysis identifies microbial determinants of post-antibiotic ecological recovery in
844 the gut. *Nat Ecol Evol*. 2020;4:1256–67.
- 845 71. Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P. The resilience of the intestinal
846 microbiota influences health and disease. *Nat Rev Microbiol*. 2017;15:630–8.
- 847 72. Hooper LV, Littman DR, Macpherson AJ. Interactions Between the Microbiota and the
848 Immune System. *Science*. 2012;336:1268–73.
- 849 73. Martino C, Dilmore AH, Burcham ZM, Metcalf JL, Jeste D, Knight R. Microbiota
850 succession throughout life from the cradle to the grave. *Nat Rev Microbiol*. 2022;20:707–20.
- 851 74. Ng KM, Aranda-Díaz A, Tropini C, Frankel MR, Treuren WV, O’Loughlin CT, et al.
852 Recovery of the Gut Microbiota after Antibiotics Depends on Host Diet, Community Context,
853 and Environmental Reservoirs. *Cell Host Microbe*. 2019;26:650-665.e4.
- 854 75. Fiorenza S, Turtle CJ. Associations between the Gut Microbiota, Immune Reconstitution,
855 and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation. *Immunometabolism*.
856 2021;3:e210004.
- 857 76. Ingham AC, Kielsen K, Cilieborg MS, Lund O, Holmes S, Aarestrup FM, et al. Specific
858 gut microbiome members are associated with distinct immune markers in pediatric
859 allogeneic hematopoietic stem cell transplantation. *Microbiome*. 2019;7:131.
- 860 77. Miltiados O, Waters NR, Andrlová H, Dai A, Nguyen CL, Burgos da Silva M, et al. Early
861 intestinal microbial features are associated with CD4 T-cell recovery after allogeneic
862 hematopoietic transplant. *Blood*. 2022;139:2758–69.
- 863 78. Staffas A, Silva MB da, Slingerland AE, Lazrak A, Bare CJ, Holman CD, et al. Nutritional

864 Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone
865 Marrow Transplantation in Mice. *Cell Host Microbe*. 2018;23:447-457.e4.

866 79. Nath S, Zilm P, Jamieson L, Kapellas K, Goswami N, Ketagoda K, et al. Development
867 and characterization of an oral microbiome transplant among Australians for the treatment of
868 dental caries and periodontal disease: A study protocol. *PLOS ONE*. 2021;16:e0260433.

869 80. Abdill RJ, Adamowicz EM, Blekhman R. Public human microbiome data are dominated
870 by highly developed countries. *PLOS Biol*. 2022;20:e3001536.

871 81. Jin S, Wetzel D, Schirmer M. Deciphering mechanisms and implications of bacterial
872 translocation in human health and disease. *Curr Opin Microbiol*. 2022;67:102147.

873 **Acknowledgements**

874 Not applicable.

875 **Funding**

876 VH was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP,
877 process no. 13996-0/2018). FHK was supported by FAPESP (process no. 16854-4/2015).

878 **Author information**

879 **Authors and Affiliations**

880 *Centro de Oncologia Molecular, Hospital Sírio-Libanês, São Paulo, SP, Brazil*

881 Vitor Heidrich, Franciele H. Knebel, Julia S. Bruno, Wanessa Miranda-Silva, Paula F.

882 Asprino, Eduardo R. Fregnani, Anamaria A. Camargo

883 *Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo,*

884 *SP, Brazil*

885 Vitor Heidrich

886 *Centro de Oncologia, Hospital Sírio-Libanês, São Paulo, SP, Brazil*

887 Luciana Tucunduva, Yana Novis

888 *Hospital Nove de Julho, Rede DASA, São Paulo, SP, Brazil*

889 Vinícius C. de Molla, Celso Arrais-Rodrigues

890 *Universidade Federal de São Paulo, São Paulo, SP, Brazil*

891 Vinícius C. de Molla, Celso Arrais-Rodrigues

892 *Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo/Instituto do*

893 *Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil*

894 Vanderson Rocha

895 **Contributions**

896 EFR and AAC designed the study. VCM, LT, VR, YN, and CAR recruited and clinically
897 evaluated volunteers. VCM collected data from clinical records. WMS collected oral
898 samples. FHK processed most of the samples. FHK and PFA performed the sequencing. VH
899 and AC conceptualized the analysis. VH performed all bioinformatics and statistical
900 analyses. VH, JSB, and AAC contributed to the interpretation of results. VH and AAC wrote
901 the original draft of the manuscript. VH, JSB, VCM, PFA, CAR, and AAC reviewed and
902 edited the manuscript. All authors read and approved the final manuscript.

903 **Corresponding author**

904 Correspondence to Anamaria A. Camargo.

905 **Ethics declarations**

906 **Ethics approval and consent to participate**

907 This study was approved by the Ethics Committee of Hospital Sírio-Libanês (#HSL 2016-08),
908 in line with the Declaration of Helsinki. All patients provided their written informed consent to
909 participate.

910 **Consent for publication**

911 Not applicable.

912 **Competing interests**

913 The authors declare that they have no competing interests.

914 **Figure legends**

915 **Figure 1**

916 **a** Principal Coordinate Analysis (PCoA) of microbiota distances (weighted UniFrac) between oral sites
917 for each timepoint. Ellipsoids indicate 95% confidence intervals. **b** Magnitude (PERMANOVA F) of
918 distances (weighted UniFrac) between oral sites per timepoint. **c** Minimum distance (weighted
919 UniFrac) between oral sites within patients per timepoint. Mann-Whitney U test was used with
920 preconditioning (P) as the reference for comparisons. **d** Number of differentially abundant genera
921 (ANCOM-BC) between oral sites per timepoint. GCF, gingival crevicular fluid; OM, oral mucosa; SB,
922 supragingival biofilm; A, aplasia; E, engraftment; E30, 30 days after engraftment; E75, 75 days after
923 engraftment; **, P-value < 0.01; ***, P-value < 0.001.

924 **Figure 2**

925 **a** Diversity (Gini-Simpson) per timepoint for each oral site. Mann-Whitney U test was used with
926 preconditioning (P) as the reference for comparisons. **b** Diversity resistance, resilience, and stability
927 (see Methods) per oral site. Mann-Whitney U test was used. Distance to P centroid (weighted
928 UniFrac) per timepoint for each oral site. Mann-Whitney U test was used with P as the reference for
929 comparisons. **d** Magnitude (PERMANOVA F) of distances (weighted UniFrac) between P and other
930 timepoints for each site. GCF, gingival crevicular fluid; OM, oral mucosa; SB, supragingival biofilm; A,
931 aplasia; E, engraftment; E30, 30 days after engraftment; E75, 75 days after engraftment; *, P-value <
932 0.05; **, P-value < 0.01; ***, P-value < 0.001; ****, P-value < 0.0001.

933 **Figure 3**

934 **a** Mean genera relative abundances (RA) per timepoint for each oral site. Genera with >2% mean RA
935 in any combination of oral site and timepoint are shown. **b** Mean genera RA ranking per timepoint for
936 each oral site. Top-10 genera are shown. **c** Differentially abundant genera (ANCOM-BC) between P
937 and other timepoints for each site. GCF, gingival crevicular fluid; OM, oral mucosa; SB, supragingival
938 biofilm; P, preconditioning; A, aplasia; E, engraftment; E30, 30 days after engraftment; E75, 75 days

939 after engraftment; *, q-value < 0.05; **, q-value < 0.01; ***, q-value < 0.001; z, ANCOM-BC structural
940 zero.

941 **Figure 4**

942 **a-c** Proportion of blooming events per oral site (a), timepoint (b) and genus (c). **d** Number of blooming
943 events per genus in each oral site. GCF, gingival crevicular fluid; OM, oral mucosa; SB, supragingival
944 biofilm; A, aplasia; E, engraftment; E30, 30 days after engraftment; E75, 75 days after engraftment.

945 **Figure 5**

946 **a** Antibiotic agents used by each patient between preconditioning (P) and 30 days after engraftment
947 (E30). **b** Time of antibiotic administration (LOT: length of therapy; DOT: days of therapy) among
948 patients showing and not showing blooms between P and E30. **c** Patient #2: genera relative
949 abundance dynamics for each oral site (top) and antibiotic usage timeline (bottom). Genera with >1%
950 mean relative abundance in any combination of oral site and timepoint are shown. GCF, gingival
951 crevicular fluid; OM, oral mucosa; SB, supragingival biofilm; A, aplasia; E, engraftment; E75, 75 days
952 after engraftment; SC, stem-cell; vanc, vancomycin; tige, tigecycline; tazo, piperacillin tazobactam;
953 poli, polymyxin B; mero, meropenem; line, linezolid.

954 **Figure 6**

955 **a** Relationship between diversity resistance, resilience, and stability values calculated for each
956 patient. **b** Extent of compositional shifts (weighted UniFrac) between consecutive timepoints (adjusted
957 for the time in days between timepoints) for each oral site. The line indicates the median value per
958 interval. **c** Distance (weighted UniFrac) to timepoint centroid per timepoint for each oral site. Mann-
959 Whitney U test was used with preconditioning (P) as the reference for comparisons. **d** Pairwise
960 distances (weighted UniFrac) per timepoint (all-against-all) for each oral site. Mann-Whitney U test
961 was used with P as the reference for comparisons. **e** Distance to P (weighted UniFrac) at engraftment
962 (E) and 30 days after engraftment (E30) for each patient for each oral site. The thick line indicates the
963 median value at each timepoint. GCF, gingival crevicular fluid; OM, oral mucosa; SB, supragingival
964 biofilm; A, aplasia; E75, 75 days after engraftment; **, P-value < 0.01; ***, P-value < 0.001; ****, P-
965 value < 0.0001.

966 **Figure 7**

967 **a** Principal Coordinate Analysis (PCoA) with representative microbiota trajectories of an oral mucosa
968 (OM) recoverer and non-recoverer. **b** Recovery classifications per site for each patient. Patient #1 OM
969 recovery could not be evaluated due to missing samples. **c-d** Kaplan-Meier curves comparing overall
970 survival (c) and progression-free survival (d) among OM recoverers (R) and non-recoverers (NR). **e**
971 Cumulative incidence curves of relapse among OM R and OM NR. **f-h** multivariate analysis for overall
972 survival (f), progression-free survival (g), and risk of relapse (h). Each model includes OM recovery
973 and the clinical variables that are relevant for each outcome. P, preconditioning; A, aplasia; E,
974 engraftment; E30, 30 days after engraftment; E75, 75 days after engraftment; HR, hazard ratio; DRI,
975 disease risk index; DOT, days of antibiotic therapy; Cond Int, conditioning intensity.

976 **Figure 8**

977 **a** Diversity (Gini-Simpson) among oral mucosa (OM) recoverers and non-recoverers for each
978 timepoint. Mann-Whitney U test was used. **b** Correlation between diversity (Gini-Simpson) at
979 preconditioning (P) and the compositional distance (weighted UniFrac) between P and 30 days after
980 engraftment (E30) for each oral site. Spearman's rank correlation test was used. **c** Blood cell counts
981 among OM recoverers and non-recoverers per timepoint for each blood cell type. Red dotted
982 horizontal lines indicate normal counts (within reference values). Mann-Whitney U test was used. A,
983 aplasia; E, engraftment; E75, 75 days after engraftment; *, P-value < 0.05; **, P-value < 0.01.

984 **Supplementary information**

985 **Additional file 1: Timelines of antibiotic usage.**





986 Antibiotic usage timelines for each patient in relation to stem-cell infusion. Red
987 dashed line indicates preconditioning sampling. Red solid line indicates stem-cell infusion.
988 Blue solid line indicates stem-cell engraftment. Blue dashed line indicates 30 days after
989 engraftment sampling. clav, amoxicillin clavulanate; tazo, piperacillin tazobactam; amox,
990 amoxicillin; cefe, cefepime; mero, meropenem; metr, metronidazole; ceft, ceftriaxone; vanc,
991 vancomycin; teic, teicoplanin; cipr, ciprofloxacin; levo, levofloxacin; doxi, doxycycline; ampi,
992 ampicillin; clar, clarithromycin; bact, sulfamethoxazole trimethoprim; erta, ertapenem; poli,
993 polymyxin b; dapt, daptomycin; line, linezolid; tige, tigecycline; amic, amikacin.





994 **Additional file 2: Supplementary tables and figures.**

995 Supplementary material with 9 tables and 14 figures.


996 **Additional file 3: Supplementary methods.**

997 Supplementary text to the Materials and methods section.




a**b****c****d**

a






medRxiv preprint doi: <https://doi.org/10.1101/2022.11.19.22282520>; this version posted November 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

b




c







a








b




c







a Timepoint ● P ● A ● E ● E30




b




c




Number at risk




d




Number at risk




e




Number at risk



f



g



h

